Promoting RNA Drug Development and Global Commercialization

Algnomics, a company developing RNA-based gene therapies, announced on the 24th that it will join Lilly Gateway Labs, located in San Diego, United States.

Alginomics Company Logo Image. Alginomics

Alginomics Company Logo Image. Alginomics

View original image

Lilly Gateway Labs is a bio-innovation hub that provides bio companies with wet lab facilities as well as opportunities for interaction with Eli Lilly researchers and executives. Together with Lilly Ventures, Lilly Explore R&D, and Lilly TuneLab, it forms part of Lilly’s biotech support program, 'Lilly Catalyze360.'


Through its entry into this facility, Algnomics plans to accelerate the development of therapeutic candidates utilizing its gene bank of over 200 target diseases. Over the long term, the company also aims to establish a global clinical infrastructure for its core pipelines, expand global partnerships, and secure local research talent in the United States.



Sungwook Lee, CEO of Algnomics, stated, “Becoming part of the biotech cluster led by Eli Lilly represents a meaningful milestone for Algnomics’s RNA platform,” and added, “Based on collaboration with the global biotech ecosystem, we will advance the development and commercialization of RNA therapies.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing